Back | Next |
home / stock / bcyp / bcyp message board
Subject | By | Source | When |
---|---|---|---|
I must be out of the loop. I | nhra3361 | investorshub | 06/11/2016 2:22:04 AM |
We'd all like to see some results here, soon! | wishmd | investorshub | 06/10/2016 5:55:20 PM |
So it appears people spent this weekend mulling | benandemmiboo | investorshub | 05/23/2016 4:29:49 PM |
So many red days. | willlbone | investorshub | 05/20/2016 5:36:39 PM |
They always talk a good game. The problem | nhra3361 | investorshub | 05/19/2016 11:36:37 PM |
the pps tells me don't waste my precious | ipnoob | investorshub | 05/19/2016 8:04:47 PM |
Just listened to the conf call agin. So... | wishmd | investorshub | 05/19/2016 7:42:51 PM |
settled? how much? possibly $2? yes with no | ipnoob | investorshub | 05/19/2016 4:03:18 PM |
Well, judging from the selloff in the last | wishmd | investorshub | 05/18/2016 11:46:21 PM |
The transcript was the most positive, and optimistic | benandemmiboo | investorshub | 05/17/2016 12:38:04 PM |
More selling tomorrow. | willlbone | investorshub | 05/16/2016 9:33:51 PM |
From the looks of the PPS the last | nhra3361 | investorshub | 05/11/2016 7:55:43 PM |
Are we all ready for dilution. Need to | nhra3361 | investorshub | 03/24/2016 2:41:15 AM |
$BLUE NEWS:::::PRESS RELEASE http://finance.yahoo.com/news/blue-calypso-r | notaclueyet | investorshub | 03/22/2016 9:02:53 PM |
yes...but they will have more support from more | ipnoob | investorshub | 03/04/2016 7:15:38 PM |
agree.......but that cost money. | nhra3361 | investorshub | 03/04/2016 7:14:08 PM |
they need to uplist to nasqad | ipnoob | investorshub | 03/04/2016 6:03:25 PM |
Zero debt | nhra3361 | investorshub | 03/04/2016 5:58:40 PM |
ok | notaclueyet | investorshub | 03/04/2016 5:34:23 PM |
not enough to pay salary and some court filings... | ipnoob | investorshub | 03/04/2016 5:31:34 PM |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc Com Company Name:
BCYP Stock Symbol:
OTCMKTS Market:
SAB Biotherapeutics Inc Com Website:
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated ...
SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies (fully-human polyc...